REG-4basebio Plc: Leadership Changes

4BasebioAnnouncement

Tue 07:02

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018.

10 February 2026

4basebio PLC

("4basebio" or the "Company")

Leadership Changes

Cambridge, UK, 10 February 2026                               – 4basebio
PLC (AIM: 4BB), an innovation driven biotechnology company enabling and
accelerating development of advanced therapy medicinal products (ATMPs)
through its high performant GMP-grade synthetic DNA products                  
                             ,                                              
announces that Dr Amy Walker has been appointed as Chief Executive Officer,
succeeding Dr Heikki Lanckriet, Founder of the Company.

After six years in the role, Heikki has stepped down as CEO in order to lead a
newly formed entity which will be focussed on advancing the Hermes
nanoparticle platform into the clinic. The Board and Executive Leadership team
determined that Amy, with her deep knowledge of the company and
commercially-focussed skillset and experience, is the right candidate to
succeed Heikki as the Company prepares for accelerated commercial growth.
Heikki will remain on the Board and will also continue to support the
Company’s scientific and technical leadership. David Roth will join Heikki
in the newly formed entity and will step down as Chief Financial Officer and
as a Director, following an orderly handover period.

Amy has been with the Company for more than five years most recently serving
as Chief Operating Officer. She has played a key role in scaling 4basebio’s
GMP manufacturing capabilities, strengthening direct engagement with top-tier
biopharma customers and supporting the Company’s growth operationally and
strategically. As Chief Executive Officer, Amy will lead an accelerated
commercial growth strategy, focusing on deepening penetration of the synthetic
DNA market as customers increasingly seek alternatives to plasmid DNA, and
building on the Company’s recent GMP milestone to support clinical
programmes in cell and gene therapy and vaccine development.

Since the Company’s formation in 2020, Heikki has been responsible for
leading 4basebio as it scaled its synthetic DNA technology from concept to
clinic, built a global customer base and stewarded 4basebio in building its
high-quality investor base.

This leadership change comes at a time when the Company enters an expected
period of accelerated commercial growth in 2026 following a successful 2025.
4basebio has top tier pharma clients in the clinic and a strong and growing
pipeline. The trend of drug development companies transitioning from plasmid
DNA to synthetic DNA and RNA continues to gain traction and supports the
Company’s commercial momentum, and we are pleased to have Amy at the helm of
this exciting phase of the Company’s development.

Dr Manja Boerman, Executive Chair of 4basebio, commented                      
                       : “4basebio’s GMP synthetic DNA manufacturing
services help accelerate development timelines for cell and gene therapies and
vaccines and offer superior safety and efficacy compared with plasmid DNA, two
critical factors for clinical success. With GMP certification for its
facility, the Company is now accelerating its focus on commercial delivery.
Amy has invaluable commercial, scientific and technical expertise and has
spearheaded building out the GMP infrastructure to enable 4basebio to lead
this dynamic market. I’m delighted that she will lead the Company through
this critical next phase of development and I look forward to leveraging my
extensive CDMO experience in helping drive the business forward.

“On behalf of the Board and Executive Management Team, I’d like to thank
Heikki for the leadership and vision that has brought the Company to a global
market leadership position. We wish him the best with his new venture and are
pleased he will continue to provide his valued strategic insights and
technical support as he continues to serve on the Board as a technical expert.
We will continue to build out the commercial and operational expertise of the
Company and strengthen the team at this extremely exciting time               
                                               .                              
                                The Company would also like to thank David for
his stewardship.”

Dr Amy Walker commented                                              : “I am
honoured to be appointed Chief Executive Officer at a time when 4basebio is
poised for significant commercial traction. I look forward to leading the
exceptional 4basebio team, accelerating our commercial momentum and scaling
our GMP grade synthetic DNA offering to support our customers, while
continuing to build long-term value for all stakeholders and, ultimately,
patients.”

Dr Heikki Lanckriet added                              : “Leading 4basebio
has been an exceptional privilege. Having founded the Company over six years
ago and built it to where it is today, I feel the time is right to hand over
the reigns as the Company moves into its next phase of commercial and
operational development. Amy and I have worked closely together over the past
years and she has been instrumental in the growth and success of 4basebio. Her
expertise and judgement will lead the Company to commercial success and I am
delighted that she will succeed me as Chief Executive Officer. With the
Company under excellent stewardship, I am excited to be able to focus on my
passion for entrepreneurship and business creation but I will continue to
support Amy, the Board and the wider team to deliver on the Company’s goals.
Finally, I would like to thank the 4basebio team for their commitment to the
Company. It has been a genuine honour for which I am very grateful.”

Michael Wasserman, COO of Elevage Medical Technologies, commented:            
                                                "We are extremely excited
about 4basebio's move into GMP-grade drug substance manufacturing and the
significant opportunity ahead for synthetic DNA in cell and gene therapy. Amy
has been instrumental in positioning the company to capture this market
inflection—her commercial vision, operational rigour and deep customer
relationships make her the ideal leader to accelerate 4basebio's next phase of
growth. We look forward to supporting the company as it scales its
differentiated synthetic DNA platform to serve our partners' innovative
programmes in the clinic."

This announcement contains inside information for the purposes of Article 7 of
EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse
(Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:

 4basebio PLC                                                                                               +44 (0)12 2396 7943  
 Dr Amy Walker, CEO                                                                                                              
                                                                                                                                 
 Cairn Financial Advisers LLP (Nominated Adviser                                    )                       +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                                                                          
                                                                                                                                 
 Cavendish Capital Markets Limited (Joint Broker)                                                           +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                                                                                        
                                                                                                                                 
 RBC Capital Markets (Joint Broker)                                                                         +44 (0)20 7653 4000  
  Kathryn Deegan / Matthew Coakes                                                                                                
 ICR Healthcare (Media and Investor Relations                                                               +44 (0)203 707 5700  
                   Mary-Jane Elliott / Jessica Hodgson                                                                           

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.

About Elevage Medical Technologies

Elevage Medical Technologies is a platform established by Patient Square
Capital and is dedicated to supporting medical technology companies that can
meaningfully improve health outcomes and quality of life for patients. Elevage
provides capital along with deep technical, regulatory, and operational
expertise to companies ranging from advanced clinical development to
commercial acceleration stage. Elevage supports rapidly growing, highly
differentiated companies with paradigm shifting technologies and strives to
help build industry leading medical technologies. To learn more about Elevage,
please visit                                www.elevagemedical.com

Forward-looking statements

This announcement may contain certain statements about the future outlook for
4basebio.  Although the directors believe their expectations are based on
reasonable assumptions, any statements about future outlook may be influenced
by factors that could cause actual outcomes and results to be materially
different.



Copyright (c) 2026 PR Newswire Association,LLC. All Rights Reserved